Healthcare -
Biotechnology - NASDAQ - US
$ 7.02
-2.77 %
$ 712 M
Market Cap
-6.88
P/E
1. INTRINSIC VALUE
2. FUNDAMENTAL
ANALYSIS
Price Chart DAWN
FINANCIALS
Balance Sheet
Day One Biopharmaceuticals, Inc.
| Current Assets | 562 M |
| Cash & Short-Term Investments | 532 M |
| Receivables | 13.9 M |
| Other Current Assets | 16.7 M |
| Non-Current Assets | 20.5 M |
| Long-Term Investments | 0 |
| PP&E | 4.71 M |
| Other Non-Current Assets | 15.8 M |
| Current Liabilities | 73.5 M |
| Accounts Payable | 3.26 M |
| Short-Term Debt | 20 K |
| Other Current Liabilities | 70.2 M |
| Non-Current Liabilities | 6.59 M |
| Long-Term Debt | 2.59 M |
| Other Non-Current Liabilities | 3.99 M |
EFFICIENCY
Earnings Waterfall
Day One Biopharmaceuticals, Inc.
| Revenue | 131 M |
| Cost Of Revenue | 5.28 M |
| Gross Profit | 126 M |
| Operating Expenses | 343 M |
| Operating Income | -217 M |
| Other Expenses | -122 M |
| Net Income | -95.5 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Day One Biopharmaceuticals, Inc.
| Net Income | -95.5 M |
| Depreciation & Amortization | 1.56 M |
| Capital Expenditures | -2.17 M |
| Stock-Based Compensation | 48.3 M |
| Change in Working Capital | 0 |
| Others | -32.4 M |
| Free Cash Flow | -80.3 M |
Wall Street Analysts Price Targets
Day One Biopharmaceuticals, Inc.
Wall Street analysts predict an average 1-year price target for DAWN of $35.4 , with forecasts ranging from
a
low of
$24 to a high of $45 .
DAWN Lowest Price Target
Wall Street Target
24 USD
241.88%
DAWN Average Price Target
Wall Street Target
35.4 USD
404.68%
DAWN Highest Price Target
Wall Street Target
45 USD
541.03%
4. DIVIDEND
ANALYSIS
DAWN does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Day One Biopharmaceuticals, Inc.
Sold
0-3 MONTHS
252 K USD 3
3-6 MONTHS
1.29 M USD 4
6-9 MONTHS
689 K USD 4
9-12 MONTHS
3.91 M USD 5
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
82.8 USD 1
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Joey Perrone - SVP, Finance and IR Jeremy Bender - CEO Lauren Merendino - CCO Charles York - COO and CFO Conference Call Participants Andrea Newkirk - Goldman Sachs Tara Bancroft - TD Cowen Joe Catanzaro - Piper Sandler Alec Stranahan - Bank of America Andres Maldonado - H.C. Wainwright Operator Hello, ladies and gentlemen, and welcome to the Day One Biopharmaceuticals Fourth Quarter and Full Year 2024 Financial and Operating Results Conference Call.
seekingalpha.com
- 1 month ago
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates
Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.69 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to loss of $0.64 per share a year ago.
zacks.com
- 1 month ago
Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress
Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively
globenewswire.com
- 1 month ago
Does Day One Biopharmaceuticals (DAWN) Have the Potential to Rally 193.16% as Wall Street Analysts Expect?
The mean of analysts' price targets for Day One Biopharmaceuticals (DAWN) points to a 193.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
zacks.com
- 2 months ago
New Strong Buy Stocks for February 13th
SYF, SSB, VCYT, DAWN and FISI have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2025.
zacks.com
- 2 months ago
Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025
BRISBANE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, February 25, 2025 at 4:30 p.m.
globenewswire.com
- 2 months ago
Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)
Day One Biopharmaceuticals focuses on pediatric cancer treatments, with a promising pipeline including tovorafenib and other targeted therapies. The stock has experienced a bearish trend but has significant upside potential, with Wall Street targeting a 190% increase. Strong financial position with $558.4M in cash and a cash runway of over 3 years significantly reducing the dilution risk.
seekingalpha.com
- 3 months ago
3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025
Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025.
zacks.com
- 3 months ago
Day One Biopharmaceuticals: Sales Figures In The Crosshairs
Day One Biopharmaceuticals' key asset, tovorafenib, shows promise in treating pediatric low-grade glioma, with ongoing phase 3 trials aiming to expand its use. DAWN's financial health is strong, with $422.8 million in cash and equivalents, ensuring sustainability for over two years despite a net loss excluding licensing revenue. The company's deep cash reserves and promising pipeline, including the new DAY301 agent, provide a solid foundation for future growth and drug development.
seekingalpha.com
- 3 months ago
Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference
BRISBANE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Dr. Jeremy Bender, chief executive officer, will present during the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13 at 3:45 p.m. Pacific Time / 6:45 p.m. Eastern Time.
globenewswire.com
- 4 months ago
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
Dr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Samuel Blackman, M.D.
globenewswire.com
- 4 months ago
Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3 at 3:00 p.m. EST.
globenewswire.com
- 5 months ago
8. Profile
Summary
Day One Biopharmaceuticals, Inc. DAWN
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 712 M
Dividend Yield
0.00%
Description
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Contact
395 Oyster Point Boulevard, South San Francisco, CA, 94080
https://dayonebio.com
IPO
Date
May 27, 2021
Employees
181
Officers
Ms. Jaa Roberson
Chief People Officer
Dr. Jeremy Bender M.B.A., Ph.D.
Chief Executive Officer, President & Director
Ms. Lauren Merendino M.B.A.
Chief Commercial Officer
Dr. Elly Barry M.D.
Chief Medical Officer
Mr. Adam Dubow J.D.
General Counsel and Chief Compliance Officer
Mr. Charles N. York II, M.B.A.
Chief Operating Officer, Chief Financial Officer & Secretary
Dr. Davy Chiodin Ph.D., Pharm.D.
Chief Development Officer
Mr. John Stubenrauch Ph.D.
Chief Technology Officer